Treating the Partners of Drug Using Pregnant Women: Stage II

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00496990

Acronym

HOPE

Enrollment

158

Registered

2007-07-06

Start date

2005-10-31

Completion date

2010-06-30

Last updated

2013-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Addiction

Keywords

male, female, couple, cocaine, opiate, methadone, detoxification, pregnancy

Brief summary

This is a two group randomized design that will compare a novel therapy package (i.e., Research supported treatment intervention, Contingency-based voucher incentives for the male partner's drug abstinence, Specialized MI couples counseling) to standard care for helping drug using partners of drug dependent pregnant women obtain and maintain drug abstinence. Participants will be followed for 22 weeks and have scheduled twice weekly urine sample collection and all participants will have follow-up interviews post-study entry.

Interventions

BEHAVIORALcontrol

this group receives the opportunity to participate in a support group

BEHAVIORALEnhanced care

this group received counseling, contingency management and methadone or detoxification

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* are 18 years of age or older on admission; * Pregnant as determined by sonogram results * have a current sexual partner who they have seen recently at least 3 times a week * male partner has regular alcohol or illicit drug use (at least 4 of 7 days typical use) and is not incarcerated.

Exclusion criteria

* woman or partner report current suicidal ideation * woman or partner meet diagnostic criteria for a current DSM-IV Axis I thought disorder (i.e. schizophrenia) * woman or partner demonstrate significant cognitive impairment that precludes them from completing the initial assessment battery * woman has evidence of physical violence or abuse

Design outcomes

Primary

Measure	Time frame
Partner Objective Substance Use	treatment entry until 28 weeks later

Secondary

Measure	Time frame
Woman's drug use will be measured with urine toxicology	treatment entry until 28 weeks later

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026